CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt-Reference-Cited by-同舟云学术

CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt

Published:2015-02 Issue:2 Volume:62 Page:332-339
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Berres Marie-Luise,Asmacher Sonja,Lehmann Jennifer,Jansen Christian,Görtzen Jan,Klein Sabine,Meyer Carsten,Strunk Holger M.,Fimmers Rolf,Tacke Frank,Strassburg Christian P.,Trautwein Christian,Sauerbruch Tilman,Wasmuth Hermann Elard,Trebicka Jonel

Publisher

Elsevier BV

Subject

Hepatology

Reference37 articles.

1. Mechanisms of hepatic fibrogenesis;Friedman;Gastroenterology,2008

2. Complications of cirrhosis. Portal hypertension;Bosch;J Hepatol,2000

3. Functional role of chemokines in liver disease models;Sahin;Nat Rev Gastroenterol Hepatol,2010

4. Chemokines in liver inflammation and fibrosis;Wasmuth;Semin Liver Dis,2010

5. CXCR3 axis in patients with primary biliary cirrhosis: a possible novel mechanism of the effect of ursodeoxycholic acid;Manousou;Clin Exp Immunol,2013

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of Liver Failure on the Immune System;International Journal of Molecular Sciences;2024-09-01

2. Vagus nerve modulates acute-on-chronic liver failure progression via CXCL9;Chinese Medical Journal;2024-06-28

3. Soluble urokinase plasminogen activator receptor levels predict survival in patients with portal hypertension undergoing TIPS;JHEP Reports;2024-05

4. In vivo investigation of the anti-liver fibrosis impact of Balanites aegyptiaca/ chitosan nanoparticles;Biomedicine & Pharmacotherapy;2024-03

5. Association between endotoxemia and blood no in the portal circulation of cirrhotic patients: results of a pilot study;Internal and Emergency Medicine;2024-02-26